Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"cognition in schizophrenia"”.
-
Anticholinergic Impact On Cognition In Schizophrenia
<p>This secondary analysis examined the relationship between the total anticholinergic load and scores on cognitive tests in 94 patients diagnosed with schizophrenia or schizoaffective disorder. Cognitive impairment is a core feature of schizophrenia, and studies have shown that it is a strong …
-
The genetics of cognition in Schizophrenia
… impairment is a well-documented feature of schizophrenia and a major determinant of functional outcomes. Cognitive function may be assessed by measuring mean performance measures on cognitive tasks or by measuring variability in performance across tasks or trials of a task that make up a …
-
The genetics of cognition in Schizophrenia
… impairment is a well-documented feature of schizophrenia and a major determinant of functional outcomes. Cognitive function may be assessed by measuring mean performance measures on cognitive tasks or by measuring variability in performance across tasks or trials of a task that make up a …
-
Investigating cortical arousal and cognition in schizophrenia and methamphetamine-induced psychotic disorder: an electroencephalography and cytokine study
Introduction: Schizophrenia (SCZ) and methamphetamine-induced psychotic disorder (MPD), are psychotic disorders characterized by positive symptoms (e.g., hallucinations and delusions), negative symptoms (e.g., social withdrawal, apathy), and impaired cognitive function. Despite the overlap in the …
-
Validation of an animal model of cognitive dysfunction associated with schizophrenia. Development and validation of the novel object recognition task using behavioural manipulations and psychotomimetic dosing regimens to induce cognitive deficits of relevance to schizophrenia in hooded-Lister rats.
Phencyclidine (PCP) is a non-competitive NMDA receptor antagonist that has been shown to induce schizophrenia-like psychotic symptoms that are clinically indistinguishable from schizophrenia in patients. When administered to rodents, PCP produces an array of behaviours that are characteristic of …